Demethylation of the miR-146a promoter by 5-Aza-2’-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Demethylation of the miR-146a promoter by 5-Aza-2’-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer ; volume:14 ; number:1 ; day:2 ; month:5 ; year:2014 ; pages:1-11 ; date:12.2014
BMC cancer ; 14, Heft 1 (2.5.2014), 1-11, 12.2014
- Urheber
-
Wang, Xiaolu
- Beteiligte Personen und Organisationen
-
Gao, Haitao
Ren, Lixin
Gu, Junfei
Zhang, Yanping
Zhang, Yong
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-14-308
- URN
-
urn:nbn:de:1111-2016030418587
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
16.08.2025, 01:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wang, Xiaolu
- Gao, Haitao
- Ren, Lixin
- Gu, Junfei
- Zhang, Yanping
- Zhang, Yong
- SpringerLink (Online service)
Ähnliche Objekte (12)
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Ailanthone: a new potential drug for castration-resistant prostate cancer
Chromogranin A: a useful biomarker in castration-resistant prostate cancer
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC)
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Ailanthone: a new potential drug for castration-resistant prostate cancer
Chromogranin A: a useful biomarker in castration-resistant prostate cancer
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC)
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Ailanthone: a new potential drug for castration-resistant prostate cancer
Chromogranin A: a useful biomarker in castration-resistant prostate cancer
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer